CompletedPhase 2

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

United States55 participantsStarted 2022-05-05

Plain-language summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Who can participate

Age range12 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ≥ 0.5 F-VASI on the face
✓. ≥ 3.0 T-VASI (body areas not including the face)
✓. Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.

What they're measuring

Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48

Timeframe: Baseline; Week 48

Trial details

NCT IDNCT05247489

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-12-19

Results submitted2024-11-26

View on ClinicalTrials.gov More Vitiligo trials